OncoMatch/Clinical Trials/NCT07247110
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Is NCT07247110 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Pembrolizumab and Cetuximab for malignant neoplasm.
Treatment: MK-4716 · Pembrolizumab · Cetuximab — Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS alteration
Disease stage
Metastatic disease required
Prior therapy
Must have received: systemic therapy — locally advanced unresectable or metastatic disease
Has received at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease
Cannot have received: immunotherapy
Exception: Arm MK-4716 + Pembrolizumab only; exclusion if discontinued from prior immunotherapy
Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institute of New Jersey ( Site 0052) · New Brunswick, New Jersey
- NEXT Oncology ( Site 0051) · Irving, Texas
- NEXT Virginia ( Site 0054) · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07247110 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS alteration is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify